RNA therapeuticsLandmark

Olpasiran and apolipoprotein B particles: what siRNA-mediated Lp(a) removal does to the apoB pool (Zimerman et al., JAMA Cardiol 2025)

Original title: Small-Interfering RNA Olpasiran and Apolipoprotein B Particles

JAMA Cardiol · 1 December 2025 · 5

Zimerman A, López JAG, Rosenson RS, Gaudet D, Baum SJ, Park JG, Wang J, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML

A JAMA Cardiology analysis from the olpasiran programme on the effect of removing Lp(a) particles on total and non-Lp(a) apoB concentrations, relevant to how much of an Lp(a) drug's benefit could run through the apoB particle count and to interpreting apoB in treated patients. Radcliffe's news item on this analysis is in the archive.

Read the paper (DOI)PubMed

olpasiran RNA therapeutics testing

Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.